Business
Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
BERKELEY, Calif. and MAINZ, Germany, April 04, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics
About this update from Quantum Cyber N.v.
[{"type":"text","content":"BERKELEY, Calif. and MAINZ, Germany, April 04, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that three German-based companies have selected ColoAlert®, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer (CRC) into their respective corporate health programs. “At Mainz Biomed, we believe that everyone should have access to colorectal cancer screening, since almost 73,000 cases of colorectal cancer are diagnosed annually in Germany,” said Guido Baechler, Chief Executive Officer of Mainz Biomed. “Including ColoAlert in corporate health programs provides an easy way for employees to get the testing they need. Early CRC detection and diagnosis enables employees to receive better treatment options that may lead to improved outcomes. We look forward to working with these three new companies and applaud their commitment to making employee health an integral part of their culture.” Mainz Biomed offers an online portal through which employees can register to be sent the ColoAlert® test. Once the sample is received and processed, confidential test results are sent back to the employee through the portal, along with an explanation of the results. If an employee has approved for their physician to be notified of test results, then the doctor may directly follow-up with the patient. As part of its commitment to the BGM program, Mainz Biomed provides education to employees and physicians on CRC and recommendations for next steps. About ColoAlert®ColoAlert®, Mainz Biomed’s flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert® detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis (Gies et al., 2018). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs and via direct sales. To receive marketing approval in the US, ColoAlert® will be evaluated in the FDA-registration trial ...